Jennifer Sherr MD, PhD’s passion for the care of those with type 1 diabetes (T1D) is quite personal, as she was diagnosed in 1987. From the time of her diagnosis, she was determined to become a pediatric endocrinologist. She completed her undergraduate and medical school training through an accelerated Joint BA/MD program at Rutgers University and the University of Medicine and Dentistry of New Jersey- Robert Wood Johnson Medical School. She then completed both her pediatric residency and pediatric endocrinology fellowship at Yale. While she always wanted to care for those with T1D, her eyes were open to the meaningful impact that clinical research has. She thus embarked on further training through the Yale Graduate School of Arts and Sciences Investigative Medicine Program, a PhD program designed to develop the next generation of physician scientists. Dr. Sherr has been devoted to clinical research since 2006. Her thesis examined the mechanisms responsible for the loss of the glucagon response to hypoglycemia and its relationship to residual beta-cell function. She is an expert in the field of diabetes technology and has worked on trials of continuous glucose monitors and automated insulin delivery systems. She has previously worked on projects with the type 1 diabetes exchange (T1DX) and was selected as the first Junior Pediatric Faculty Member to the T1DX Steering Committee, serving in that role from 2016-2017. Working in an NIH-funded consortium, she is co-leading the Yale site to characterize glycemia across pregnancy. In 2021, she took on the role of lead investigator at Yale for the TrialNet consortium, a group whose purpose is to prevent progression to stage 3 diabetes and preserve residual beta cell function in those who are newly diagnosed with this condition. As a Professor in the department of pediatrics, her goal in both the clinical and research realm is to reduce the burden of living with type 1 diabetes, for both her patients and herself.